IH IHE iShares U.S. Pharmaceuticals ETF Loading... : Bullish and Bearish Analyst Opinions

Schneider states a goal to "work on reducing the cost of medicines." This is standard Democratic policy rhetoric signaling continued legislative pressure on pharmaceutical pricing power. While the IRA (Inflation Reduction Act) already initiated this, continued focus suggests potential expansion of drug price negotiation lists. WATCH. Regulatory headwinds remain persistent for pure-play pharma. Gridlock in Congress preventing new legislation (bullish for Pharma).